Literature DB >> 3335638

Source of raised serum estrogens in male rats with portal bypass.

G C Farrell1, A Koltai, M Murray.   

Abstract

We sought to establish the mechanism for the raised serum estrogen levels that occur in male rats with portal hypertension and resultant portal bypass. Using the portal vein ligated (PVL) rat model, we evaluated plasma steroid hormone concentrations, metabolic clearance rate (MCR) of estradiol, and hepatic metabolism of androstenedione to estrogens and other products. In contrast to serum testosterone levels that were reduced, serum androstenedione levels were normal in the PVL rat. Estradiol MCR was measured by a constant intravenous infusion technique and was found to be similar in PVL and control animals. Androstenedione MCR was determined during constant intravenous infusion of [3H]androstenedione, and the resultant radiolabeled steroids present in plasma were separated by thin layer chromatography. The MCR of androstenedione was not diminished in PVL rats compared with controls. However, there was a sevenfold increase in the plasma estradiol derived from [3H]androstenedione in rats with portal bypass. Examination of radiolabel excreted in bile during infusion of [3H]androstenedione showed that 25-46% of this steroid was converted to estradiol in PVL rats compared with less than 3% in control male rats (P less than 0.001). Moreover, there was a selective reduction in the excretion of 16 alpha-hydroxyandrostenedione, a finding which suggested that the metabolism of androstenedione via this pathway was decreased. Androstenedione 16 alpha-hydroxylation is known to be catalyzed by a male-specific cytochrome P-450 isoform, P-450UT-A. We conclude that raised plasma estradiol levels after portal bypass in male rats are due to increased production rates, resulting in turn from enhanced aromatization of androstenedione to estradiol. On the basis of the observed specific changes in androstenedione hydroxylation pathways, it is proposed that alterations in levels of sex-specific forms of cytochrome P-450 occur in male rats with portal bypass and could account for the enhanced formation of estradiol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335638      PMCID: PMC442497          DOI: 10.1172/JCI113299

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Vascular pattern of the cirrhotic liver.

Authors:  H POPPER; H ELIAS; D E PETTY
Journal:  Am J Clin Pathol       Date:  1952-08       Impact factor: 2.493

2.  Conversion of androgens to estrogens in cirrhosis of the liver.

Authors:  G G Gordon; J Olivo; F Rafil; A L Southren
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

Review 3.  Oestrogen metabolism in liver disease.

Authors:  H Adlercreutz
Journal:  J Endocrinol       Date:  1970-01       Impact factor: 4.286

4.  A radioimmunoassay of androstenedione.

Authors:  I H Thorneycroft; W O Ribeiro; S C Stone; S A Tillson
Journal:  Steroids       Date:  1973-01       Impact factor: 2.668

5.  Effect of portacaval shunt on hepatic cytochrome P-450 in rats.

Authors:  F W Ossenberg; L Pointard; J P Benhamou
Journal:  Rev Eur Etud Clin Biol       Date:  1972-10

6.  Radioimmunoassay of plasma estrogens.

Authors:  C H Wu; L E Lundy
Journal:  Steroids       Date:  1971-07       Impact factor: 2.668

Review 7.  Sex-related differences in drug metabolism.

Authors:  R Kato
Journal:  Drug Metab Rev       Date:  1974       Impact factor: 4.518

8.  Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione.

Authors:  E A Thompson; P K Siiteri
Journal:  J Biol Chem       Date:  1974-09-10       Impact factor: 5.157

9.  Aromatization of androgens by human abdominal and breast fat tissue.

Authors:  A Nimrod; K J Ryan
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

10.  Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone.

Authors:  R Horton; J F Tait
Journal:  J Clin Invest       Date:  1966-03       Impact factor: 14.808

View more
  5 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis.

Authors:  E Cantrill; M Murray; I Mehta; G C Farrell
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

3.  Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis.

Authors:  Yoshiyuki Takahara; Mitsuo Takahashi; Hiroki Wagatsuma; Fumihiko Yokoya; Qing-Wei Zhang; Mutsuyo Yamaguchi; Hiroyuki Aburatani; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

4.  Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.

Authors:  Jason D Robarge; Djane B Duarte; Behzad Shariati; Ruizhong Wang; David A Flockhart; Michael R Vasko
Journal:  Exp Neurol       Date:  2016-04-09       Impact factor: 5.330

5.  Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet.

Authors:  Husna Yetti; Hisao Naito; Yuan Yuan; Xiaofang Jia; Yumi Hayashi; Hazuki Tamada; Kazuya Kitamori; Katsumi Ikeda; Yukio Yamori; Tamie Nakajima
Journal:  PLoS One       Date:  2018-02-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.